Corbus Pharmaceuticals

Corbus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company .

Corbus Pharmaceuticals, Inc. is a privately held Boston-based clinical stage pharmaceutical company focusing on the treatment of multiple rare ('orphan') inflammatory-fibrotic diseases with clear unmet needs. Our lead compound Resunab is a novel synthetic anti inflammatory drug with a superior safety profile to current anti-inflammatory drugs on the market and promising pre-clinical potency. Resunab is orally bioavailable and targets inflammation and fibrosis by triggering the production of the anti-inflammatory eicosanoids LXA4 and PGJ2 while inhibiting the pro-inflammatory cytokine TGF-beta. Resunab uniquely binds to the CB2 cell memebrane receptor of immune cells and triggers the resolution of inflammation. Resunab has successfully completed Phase 1 human safety studies and is scheduled for Phase 2 studies in cystic fibrosis and scleroderma.